Related Experiment Video

Updated: Jun 10, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

K Schmid1, Z Bago-Horvath, W Berger

  • 1Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.

British Journal of Cancer
|August 5, 2010
PubMed
Abstract

Insights

Combined inhibition of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathways shows synergistic effects in small cell lung cancer (SCLC) models. This dual-targeted therapy offers a promising new strategy for SCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Small cell lung cancer (SCLC) remains a challenging malignancy with limited therapeutic options.
  • Investigating novel therapeutic strategies targeting key signaling pathways is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of combined epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition in SCLC.
  • To explore the molecular mechanisms and therapeutic potential of this combination strategy.

Main Methods:

  • Immunohistochemistry was used to assess EGFR, p-AKT, p-ERK, p-mTOR, and p-p70s6K protein expression in 107 SCLC tumor specimens.
  • SCLC cells were treated with erlotinib (EGFR inhibitor) and RAD001 (mTOR inhibitor) to analyze cell viability, proliferation, autophagy, and pathway regulation.

Main Results:

  • EGFR, p-AKT, p-ERK, p-mTOR, and p-p70s6K were expressed in a significant proportion of SCLC tumors, with mTOR pathway activation higher in early stages.
  • EGFR expression correlated with p-ERK and p-mTOR, while p-mTOR correlated with p-p70s6K.
  • The combination of erlotinib and RAD001 demonstrated synergistic effects on cell viability, proliferation, and autophagy in SCLC cells, overcoming resistance to monotherapy.

Conclusions:

  • Combined inhibition of EGFR and mTOR pathways presents a promising therapeutic strategy for SCLC.
  • This dual-targeted approach warrants further investigation in clinical settings for SCLC treatment.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...